Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2025 14:58 ET | Source: PolTREG S.A.

PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial

PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial FDA agreed that PolTREG’s clinical data in Stage 3...
July 04, 2025 06:15 ET | Source: PolTREG S.A.

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr....
June 13, 2025 11:47 ET | Source: PolTREG S.A.

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera (https://immuthera.bio/) in Delaware to expand its...
February 27, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent the long-term effects of traumatic brain injuryFindings could translate into treating...
September 16, 2024 07:00 ET | Source: Abata

Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer

Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
August 22, 2024 07:00 ET | Source: Abata

Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis

Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
August 15, 2024 07:00 ET | Source: Abata

Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development

Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
July 09, 2024 20:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
July 09, 2024 06:00 ET | Source: Abata

Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis

Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis